Your browser doesn't support javascript.
loading
Therapeutic failure in moderate and severe psoriasis patients in a health institution - a transversal study of prevalence and demographic determinants.
Montoya-Londoño, Daniel; Gómez-Mercado, Carlos Alberto; Estrada-Acevedo, Jorge Iván; Madrigal-Cadavid, Juliana; Segura, Angela; Giraldo-Alzate, Newar Andrés; Londoño, Angela María.
Afiliación
  • Montoya-Londoño D; Generation of Value in Health Research Group, Omnivida, Medellín, Colombia.
  • Gómez-Mercado CA; Generation of Value in Health Research Group, Omnivida, Medellín, Colombia.
  • Estrada-Acevedo JI; Pharmacoepidemiology and Health Risk Management Research Group, +helPharma, Medellín, Colombia.
  • Madrigal-Cadavid J; Pharmacoepidemiology and Health Risk Management Research Group, +helPharma, Medellín, Colombia.
  • Segura A; Epidemiology and Biostatistics Research Group, CES University, Medellin, Colombia.
  • Giraldo-Alzate NA; Generation of Value in Health Research Group, Omnivida, Medellín, Colombia.
  • Londoño AM; Dermatology Research Group, CES University, Medellin, Colombia.
J Dermatolog Treat ; 33(6): 2821-2826, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35583354
BACKGROUND: Psoriasis is a chronic disease that seriously impacts quality of life. There are known genetic and environmental factors that influence its onset and progression. Even though there is no cure for it, there are a variety of treatments available today to control its symptoms, although many of them fail to do so substantially. OBJECTIVE: To identify the association of multiple sociodemographic, clinical, and pharmacological factors with therapeutic failure. METHODS: Observational, descriptive, cross-sectional, retrospective, and analytical study of therapeutic failure in patients with moderate or severe psoriasis between 2020 and 2021 was performed. RESULTS: In total 1051 patients with moderate or severe psoriasis were evaluated. Gender (ORa: 0.579 CI 95%: 0.382-0.878), type of therapy (biologic or non-biologic; ORa: 1.939 CI 95%: 1.242-3.027), age (ORa: 1.018 CI 95%: 1.003-1.034), days of treatment (ORa: 1 CI 95%: 0.999-1) and DLQI (ORa: 1.212 CI 95%: 1.172-1.253) are significantly associated with therapeutic failure. CONCLUSION: Being male and receiving biologic therapy are associated with a higher incidence of therapeutic failure in the treatment of moderate or severe psoriasis. The increase in DLQI increase in the probability of failure, and mayor age or days of treatment decrease in the probability of failure.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Calidad de Vida Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans / Male Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Calidad de Vida Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans / Male Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Reino Unido